CGN POWER (01816): Cangnan Unit 1 is ready for commercial operation.
China General Nuclear Power Corporation (01816) announced that on April 29, 2026, the first unit of CGN Cangnan Nuclear Power Co., Ltd. (Cangnan Nuclear) has completed all commissioning work and is ready for commercial operation.
CGN POWER (01816) announced that on April 29, 2026, the No. 1 unit of CGN Cangnan Nuclear Power Co., Ltd. (Cangnan Nuclear Power) has completed all commissioning work and is ready for commercial operation.
Cangnan Nuclear Power will also handle the electricity business license and other related documents according to requirements. Normally, after the relevant procedures are completed, the above-mentioned time will be recognized as the time when the unit is put into commercial operation.
After the commercial operation of Unit 1 of Cangnan Nuclear Power, the number of nuclear power units managed by the company (including joint ventures) will increase to 30, and the installed capacity of operating units will also increase from 33,040 MW to 34,248 MW.
Related Articles
STERLING GP (01825) appoints Zhang Yuan as an independent non-executive director.
JINGCHENG MAC (00187) released its first-quarter financial results, with a net loss attributable to shareholders of approximately 32.21 million yuan, an increase of about 1.7 times year-on-year.
HUTCHMED (00013): Sovleplenib, a Chinese new drug used to treat warm antibody type autoimmune hemolytic anemia patients, has received acceptance for market application and has been included in priority review and breakthrough therapy varieties.
STERLING GP (01825) appoints Zhang Yuan as an independent non-executive director.
JINGCHENG MAC (00187) released its first-quarter financial results, with a net loss attributable to shareholders of approximately 32.21 million yuan, an increase of about 1.7 times year-on-year.
HUTCHMED (00013): Sovleplenib, a Chinese new drug used to treat warm antibody type autoimmune hemolytic anemia patients, has received acceptance for market application and has been included in priority review and breakthrough therapy varieties.
RECOMMEND
